Recognises GSK3β, a ubiquitously expressed mammalian multifunctional serine/threonine
Anti-GSK-3β antibody (crb2005219)
Western blot analysis of human prostate adenocarcinoma (PC-3) whole cell extract (30µg).
Lane 1: PC-3 cells
Secondary: Goat anti-rabbit IgG conjugated to HRP (Vector) 1:2500
|Antigen Peptide||KLH conjugated synthetic peptide crb1200462e|
|Protein ID||UniProtKB - P49841|
|Aliases||Glycogen synthase kinase-3 beta, GSK3 beta, GSK3B, Serine/threonine-protein kinase GSK3B|
|Target Protein Species||human|
|Validation||WB (1:1000), ELISA (1:1000)|
|Storage Stabilisers||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
|Family||protein kinase superfamily|
|Super Family||CMGC Ser/Thr protein kinase family. GSK-3 subfamily.|
|Disease Area||Signal transduction, Biological rhythms, Carbohydrate metabolism, Differentiation, Glycogen metabolism, Neurogenesis, Wnt signaling pathway|
|Storage||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
Gao, S., Li, S., Duan, X., Gu, Z., Ma, Z., Yuan, X., Feng, X. and Wang, H. (2017). Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of oesophageal squamous cell carcinoma by modifying STAT3 activity. Mol Carcinog, 56(10), 2301-2316. PMID: 28574599
Zeng, J., Liu, D., Qiu, Z., Huang, Y., Chen, B., Wang, L., Xu, H., Huang, N., Liu, L. and Li, W. (2014). GSK3β Overexpression Indicates Poor Prognosis and Its Inhibition Reduces Cell Proliferation and Survival of Non-Small Cell Lung Cancer Cells. PLoS ONE, 9(3), e91231. PMID: 24618715
Glycogen Synthase Kinase 3 beta (GSK3β) is a multifunctional serine/threonine kinase widely expressed in most mammalian cells. GSK3β is highly active under basal conditions and acts downstream of phosphoinositide 3-kinase (PI3K) signalling. PI3K activation results in Akt phosphorylation and the subsequent phosphorylation of GSK3β at serine-9 and its inactivation. GSK3β in turn activates the production of pro-inflammatory cytokines including IL-1β, IL-6, IL-12, IL-17, TNFα and IFNγ, and supresses the production of IL-10, IL-1Ra, and IFNβ by immune cells.
Under resting conditions, GSK3β is constitutively active due to tyrosine-216 phosphorylation, and it phosphorylates and inhibits a diverse group of pro-oncogenic substrates, such as: β-catenin; cyclin D1; c-Jun; c-Myc and CREB. GSK3β is also involved in Wnt signalling pathways.
Aberrant expression of GSK3β has been shown to promote cell growth in some cancers and to suppress it in others. GSK3β inhibition leads to the accumulation of β-catenin in the nucleus, enhancing the progression of many cancers. However the inhibition of GSK3β also induces apoptosis in various types of cancers, such as pancreatic, colorectal and bladder cancer. Inhibition of GSK3β can also have neuroprotective effects on dopaminergic neurons such as in Parkinson’s disease.